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Carolyn H. McCabe, BS,* Eugene Braunwald, MD, MACC,* for the ANTHEM–TIMI-32 Investigators
Boston and Springfield, Massachusetts; Cleveland, Ohio; Birmingham, Alabama;
Louisville, Kentucky; Nottingham, United Kingdom; and San Carlos, California
Objectives We sought to evaluate the safety and efficacy of recombinant nematode anticoagulant protein c2 (rNAPc2) in
patients with non–ST-segment elevation acute coronary syndrome (nSTE-ACS).
Background Recombinant NAPc2 is a potent inhibitor of the tissue factor/factor VIIa complex that has the potential to re-
duce ischemic complications mediated by thrombin generation.
Methods A total of 203 patients were randomized 4:1 to double-blinded intravenous rNAPc2 or placebo every 48 h for a
total of 1 to 3 doses in 8 ascending panels (1.5 to 10 g/kg). All patients received aspirin, unfractionated hepa-
rin (UFH), or enoxaparin and early catheterization; clopidogrel and glycoprotein IIb/IIIa blockers were encour-
aged. Two subsequent open-label panels evaluated 10 g/kg rNAPc2 with half-dose UFH (n  26) and no UFH
(n  26). The primary end point was the rate of major plus minor bleeding. Pharmacokinetics, pharmacodynam-
ics, continuous electrocardiography, and clinical events were assessed.
Results Recombinant NAPc2 did not significantly increase major plus minor bleeding (3.7% vs. 2.5%; p  NS) despite
increasing the international normalized ratio in a dose-related fashion (trend p  0.0001). Higher-dose rNAPc2
(7.5 g/kg) suppressed prothrombin fragment F1.2 generation compared with placebo and reduced ischemia by
50% compared to placebo and lower-dose rNAPc2. Thrombotic bailout requiring open-label anticoagulant occurred
in 5 of 26 patients treated without UFH, but none in the half-dose UFH group (19% vs. 0%; p 0.051).
Conclusions In patients with nSTE-ACS managed with standard antithrombotics and an early invasive approach, additional
proximal inhibition of the coagulation cascade with rNAPc2 was well tolerated. rNAPc2 doses 7.5 g/kg
suppressed F1.2 and reduced ischemia, though some heparin may be necessary to avoid procedure-related
thrombus formation. (Anticoagulation With rNAPc2 to Eliminate MACE/TIMI 32; http://www.clinicaltrial.
gov/ct/show/NCT00116012?order1; NCT00116012) (J Am Coll Cardiol 2007;49:2398–407) © 2007 by the
American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.02.065a
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June 26, 2007:2398–407 The ANTHEM–TIMI-32 Trial: TF/FVIIa Inhibitor in nSTE-ACSubendothelial tissue factor (TF) and releases microparticles
ontaining TF, a highly procoagulant material found in ele-
ated concentration in the necrotic atherosclerotic core. This
esults in the rapid initiation of platelet activation and aggre-
ation and thrombus formation (2). Current standard anti-
hrombotic therapies (heparins, aspirin, clopidogrel, glyco-
rotein [GP] IIb/IIIa blockers) do not suppress thrombin
eneration (3) and percutaneous coronary intervention (PCI)
nhances it (4). Because proximal inhibitors of the coagulation
ascade are potent inhibitors of new thrombin generation,
everal agents (5) have been developed to exploit this potential
dvantage over drugs that act more downstream in the cascade,
uch as heparins.
Recombinant nematode anticoagulant protein c2
rNAPc2) is an 85-amino acid serine protease inhibitor
ashioned after the original protein isolated from the hema-
ophagous hookworm parasite Ancylostoma caninum (6). The
nticoagulant activity results from inhibition of the catalytic
omplex of TF/tissue factor/activated factor VII (fVIIa) by
unique mechanism that requires the initial binding of
NAPc2 to zymogen or activated factor X before the
ormation of the final ternary inhibitory complex with
F/fVIIa (7) (Fig. 1). The elimination half-life in man is 50
o 60 h and is independent of dose and route of adminis-
ration (intravenous or subcutaneous) (8). Earlier studies of
NAPc2 have demonstrated that it safely and effectively
nhibits thrombin generation in patients undergoing elective
CI (9) and reduces the incidence of deep venous throm-
osis when administered prophylactically in patients under-
oing elective total knee arthroplasty (10).
The primary goal of the present phase 2 trial was to
valuate the safety and efficacy of a range of doses of
NAPc2 in patients with nSTE-ACS managed with stan-
ard therapies, including an early invasive strategy. We
ypothesized that proximal inhibition of the coagulation
ascade with rNAPc2 would reduce new thrombin genera-
ion and recurrent ischemia following nSTE-ACS without
ubstantially increasing bleeding. The heparin de-escalation
Figure 1 Mechanism of Action of rNAPc2
Tissue factor/activated factor VII (TF/fVIIa) inhibition by recombinant nematode an
zymogen factor X; 2) docking of the rNAPc2-fX complex to TF/fVIIa assembled on a
to the active site of fVIIa, resulting in a tightly bound quarternary inhibitory complehase of this study was an open-
abel pilot experience to explore
he feasibility of the stepwise
ithdrawal of heparin in patients
reated with the highest studied
ose of rNAPc2 with the goal of
ptimizing treatment simplicity,
afety, and efficacy.
ethods
atient population. The AN-
HEM–TIMI-32 (Anticoagu-
ation With rNAPc2 to Help
liminate Major Adverse Car-
iac Events–Thrombolysis In
yocardial Infarction-32) trial
as a multicenter trial consisting
f 2 parts: a randomized, double-
lind, placebo-controlled, as-
ending rNAPc2 dose-ranging
hase and a single-arm, open-
abel, stepwise, unfractionated
eparin (UFH) de-escalation pi-
ot study of 10 g/kg rNAPc2. In the dose-ranging phase,
pproximately 25 patients in each of 8 dose panels were
andomized to receive treatment with rNAPc2 or placebo in
4:1 ratio. In the UFH de-escalation phase, 2 open-label
anels of 26 patients each with half-dose or no UFH were
tudied.
Eligibility criteria included: age 18 to 75 years, hospital-
zation with moderate to high-risk nSTE-ACS with isch-
mic discomfort at rest lasting5 min consistent with ACS
ithin 48 h of randomization, and management with an
arly invasive strategy (72 h). In panels 1 to 3, moderate to
igh risk was defined as a TIMI risk score for nSTE-ACS
11) of 3. Subsequently, a protocol amendment also
ermitted patients with nSTE-ACS and either ST-segment
Abbreviations
and Acronyms
CABG  coronary artery
bypass graft
F1.2  prothrombin
fragment 1.2
GP  glycoprotein
INR  international
normalized ratio
nSTE-ACS  non–ST-
segment elevation acute
coronary syndrome
PCI  percutaneous
coronary intervention
rNAPc2  recombinant
nematode anticoagulant
protein c2
TF/fVIIa  tissue factor/
activated factor VII
TIMI  Thrombolysis In
Myocardial Infarction
UFH  unfractionated
heparin
ulant protein c2 (rNAPc2) involves the following steps: 1) rNAPc2 binds tightly to
agulant phospholipid surface; and 3) presentation of the reactive loop of rNAPc2
rNAPc2; TF  tissue factor; VIIa  fVIIa; X  factor X.ticoag
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The ANTHEM–TIMI-32 Trial: TF/FVIIa Inhibitor in nSTE-ACS June 26, 2007:2398–407eviation 0.5 mm (depression or transient elevation) or an
levated cardiac marker (troponin or creatinine kinase-
yocardial band) to be enrolled regardless of the TIMI risk
core.
Exclusion criteria were ST-segment elevation myocardial
nfarction, ACS due to a distinct nonatherosclerotic mech-
nism, increased bleeding risk, fibrinolytics within 24 h,
lanned coronary artery bypass graft (CABG) surgery
ithin 7 days, creatinine 4-mg/dl, anemia, aminotrans-
erase 3 times normal, allergy to aspirin, history of
eparin-induced thrombocytopenia, pregnancy, or other
Figure 2 ANTHEM–TIMI-32 Design
The study had 2 phases: (A) a double-blind, randomized, placebo-controlled, asce
In the dose-ranging phase (A), 203 patients with non-ST-segment elevation acute
4:1 to recombinant nematode anticoagulant protein c2 (rNAPc2) or matching place
patients each. In the heparin de-escalation phase (B), 26 patients received 10 g
26 patients treated with 10 g/kg rNAPc2 and no heparin. *Encouraged per curre
cardiogram; Enox  enoxaparin; GP  glycoprotein.onditions placing the patient at increased risk. In the eeparin de-escalation phase, low-molecular-weight heparin
ithin 12 h before randomization was not permitted.
The study was conducted according to the International
onference on Harmonization Good Clinical Practice
uidelines, approved by the institutional review boards/
thics committees of each center, and registered with the
ational Institutes of Health (NCT00116012). Written
nformed consent was obtained from all patients.
tudy protocol. The study design is shown in Figure 2. A
otal of 255 patients (203 randomized in a 4:1 fashion to
NAPc2 or placebo in the dose-finding phase, 52 patients
ose-ranging phase and (B) a single-arm, unblinded heparin de-escalation phase.
ry syndrome (nSTE-ACS) managed with an early catheterization were randomized
ministered intravenously (IV) every 48 h for 1 to 3 doses in 8 panels of 25
APc2 and half-dose unfractionated heparin (UFH), followed by a second panel of
ctice guidelines. †10 g/kg dose panel repeated. ASA  aspirin; ECG  electro-nding d
corona
bo ad
/kg rN
nt pranrolled in the single-arm, open-label heparin de-escalation
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June 26, 2007:2398–407 The ANTHEM–TIMI-32 Trial: TF/FVIIa Inhibitor in nSTE-ACShase) participated from 28 centers in the U.S. and Canada
etween November 2002 and May 2006. A central
andomization system was used that involved a permuted-
lock design in which assignment was blocked by site
block size of 5).
In the dose-ranging portion of the trial, we evaluated
NAPc2 doses (g/kg) of 1.5, 2.0, 3.0, 4.0, 5.0, 7.5, and
0.0 (2 panels) in a double-blind fashion compared with
lacebo. In the heparin de-escalation phase we studied 10.0
g/kg rNAPc2 (open label) without a concomitant control
roup. An independent data safety monitoring board,
uided by an algorithm designed to terminate study of an
nsafe dose (see Statistical analysis), reviewed data at the
ompletion of each panel and approved the testing of the
ext dose. Patients received intravenous study drug (single
njection over 60 s) followed by coronary angiography and
evascularization (if appropriate). Additional doses of study
rug every 48 h were permitted during hospitalization,
rovided CABG was not required and the patient did not
xperience clinically significant bleeding or other adverse
vent.
All patients received daily oral aspirin (75 to 325 mg).
he use and timing of clopidogrel, GP IIb/IIIa blockers,
nd other standard ACS therapies were encouraged per
urrent practice guidelines (12) but left to the investigator’s
iscretion.
In dose finding, either UFH (60 U/kg bolus [maximum
,000 U], 12 U/kg/h initial infusion [maximum 1,000 U/h]
itrated to an activated partial thromboplastin time [aPTT]
.5 to 2 times control) or enoxaparin (1.0 mg/kg subcuta-
eously every 12 h [every 24 h if the calculated creatinine
learance was30 ml/min]) was required. In the first 3 dose
anels, enoxaparin was the only anticoagulant permitted
etween randomization and 48 h after the last dose of study
rug. However, a protocol amendment subsequently al-
owed the use of UFH after new external data (1) demon-
trated similar outcomes between these agents. During PCI,
osing algorithms were used (see Appendix) to ensure
dequate and uniform anticoagulation.
In the first panel of the heparin de-escalation phase,
alf-dose UFH (30 U/kg bolus [maximum 2,500 U];
U/kg/h infusion [maximum 500 U/h] with no subsequent
djustment) was administered before and during coronary
ngiography/intervention. In the second panel, no addi-
ional anticoagulant was permitted between randomization
nd 48 h after the last dose of study drug (including during
CI), unless required for management of a thrombotic
omplication or other strong clinical indication (e.g.,
ABG).
lood collection and assays. Blood specimens to assess
he complete blood count (CBC), plasma drug concentra-
ion, and pharmacodynamic effect (international normalized
atio [INR], prothrombin fragment 1.2 [F1.2]) were ob-
ained at baseline, 2 to 6 h, 24 h (CBC only), 48 h (if not
ischarged), and 7 days after last study drug, and 42 days
fter randomization. The INR and F1.2 (assessed by hnzyme-linked immunoabsorbent assay [ELISA]) were
easured by Icon Laboratories (Farmingdale, New York)
sing a Stago Sta Analyzer and ELX800 Biotek instrument,
espectively. The F1.2 concentration during dose ranging
as measured using polyclonal antibodies (Enzygnost F12
ssay, reference range 0.40 to 1.10 nmol/l, sensitivity 0.04
mol/l), but this methodology was replaced by a more
pecific assay using monoclonal antibodies during the hep-
rin de-escalation phase (Enzygnost F12 [monoclonal]
ssay, reference range 69 to 229 pmol/l, sensitivity 20
mol/l) by the manufacturer (Dade Behring, Deerfield,
llinois). Plasma drug concentrations were analyzed by
LISA (panels 1 to 3 by Corvas International, San Diego,
alifornia; all other panels by Alta Bioanalytical Laborato-
ies, San Diego, California).
Blood samples were obtained at baseline and on day 42 to
ssess for the development of antibodies to rNAPc2 using
abbit polyclonal antibodies to NAPc2. If antibodies were
resent at day 42, then patients were retested again at 3 and
months, and antibodies were assessed for neutralizing
ctivity.
Local measurement of INR during dose finding was not
ermitted between randomization and 7 days after study
rug to maintain the study blind, because rNAPc2 increases
he INR in a dose-related fashion (8). The aPTT (which is
nly minimally affected by rNAPc2 [13]) was measured
aily and 6 h after any change in the UFH dose. The
ctivated clotting time was used to guide UFH dosing
uring PCI (see Appendix). Serial assessment of cardiac
arkers of necrosis were performed in the first 24 h and
fter recurrent ischemia or revascularization.
-lead electrocardiographic monitoring. All patients un-
erwent continuous ambulatory 3-lead electrocardiographic
ECG) monitoring (Lifecard CF ambulatory ECG re-
order; Reynolds Medical, Braintree, Massachusetts) for
schemia from randomization through 7 days after the last
ose of study drug. Monitoring continued during and after
CI but was terminated just before CABG surgery. Con-
inuous ECGs were assessed by a central core laboratory
linded to treatment assignment. An ischemic episode was
efined as 1.0 mm horizontal or downsloping ST-
egment depression or 1.0 mm ST-segment elevation last-
ng at least 1 min and separated from other episodes by at least
min, occurring in any of the 3 leads. Ischemic events
ccurring during catheterization or PCI were censored.
linical follow-up. Return visits to the clinic were made 7
ays after the last dose of study drug and 42 days after
andomization. Follow-up phone calls to assess for bleeding
nd intercurrent events were made at 3 and 14 days after the
ast dose and at 3 and 6 months after randomization to
ssess for death and ischemic complications.
linical end points and definitions. The prespecified
rimary end point of the study was the combined rate of
djudicated major plus minor hemorrhage using the stan-
ard TIMI criteria (14) (hereafter termed “significant”
emorrhage) from randomization through 7 days after the
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The ANTHEM–TIMI-32 Trial: TF/FVIIa Inhibitor in nSTE-ACS June 26, 2007:2398–407ast dose of study drug. A TIMI major hemorrhage was
efined as an intracranial hemorrhage or overt bleeding
ssociated with a 5 g/dl fall in hemoglobin. A TIMI
inor hemorrhage was defined as a nonintracranial overt
leed associated with a 3 to 5 g/dl decrease in hemoglobin.
dditional clinical safety end points included the rates of
ransfusions, serious adverse events, and antibody formation
o rNAPc2.
Prespecified efficacy end points included pharmacokinetic
plasma drug concentration) and pharmacodynamic (INR,
1.2) measures and the percentage of patients with ischemia
n the first 48 h on 3-lead continuous ECG. Additional
respecified ECG end points of interest included the
verage number of ischemic events per patient and the
T-product, defined as the product of the maximal extent of
T-segment deviation multiplied by the number of minutes
f deviation.
Reinfarction, clinical recurrent ischemia, and stroke were
efined with the standard TIMI definitions (15). Throm-
otic bailout (TBO) was defined as an episode of refractory
schemia occurring after administration of the first dose
hrough 7 days after the last dose of study drug that required
he use of open-label anticoagulation to manage any one of
he following complications due to thrombosis: 1) ischemia
asting 20 min despite management with standard thera-
ies other than anticoagulants; 2) clinical instability (e.g.,
ypotension); 3) a decrement in TIMI flow grade; 4) a
oronary artery dissection with decreased flow; 5) distal
mbolization; 6) side branch closure; or 7) abrupt closure of
he culprit artery. All of the clinical end points described
ere adjudicated by an independent blinded clinical event
ommittee. In suspected cases of TBO during the heparin
e-escalation phase, angiographic results assessed by a
linded central angiographic core laboratory were provided
o the event committee for consideration.
Biomarkers were obtained at baseline, 2 to 6 h, 48 h, and
days after last dose, and 42 days after randomization in the
ose-ranging phase. These included cardiac troponin I,
igh-sensitivity C-reactive protein, brain natriuretic pep-
ide, and matrix metalloproteinase 9, measured in the TIMI
iomarker Core Laboratory using established methods
Beckman Coulter AccuTnI and Hitachi 917 Analyzer;
oche Diagnostics, Indianapolis, Indiana; and Beckman
oulter Access 2 BNP; ELISA assay, R&D Systems,
inneapolis, Minnesota; respectively).
tatistical analysis. The selection of 25 patients per panel
as guided by the desire to gain experience with the use of
NAPc2 in combination with aspirin, heparins, clopidogrel,
P IIb/IIIa inhibitors, and an early invasive strategy. Safety
oundaries were set to exclude rates of significant hemor-
hage that were relatively 20% greater than the predicted
istorical control rate of 6% (i.e., absolute rate 7.2%)
ased on the observations from the National Investigators
ollaboration with Enoxaparin 3 (NICE-3) registry (16),
sing a 1-sided 95% confidence interval. In the heparin
e-escalation phase, a second safety boundary was set to rxclude a rate of TBO that was relatively 20% greater than
he historical control rate of TBO (6.2%) observed in the
EPLACE-2 (Randomized Evaluation of PCI Linking
ngiomax to Reduced Clinical Events) trial (17) (i.e.,
bsolute rate 7.44%) using a 1-sided 95% confidence
nterval, because the risk of thrombosis with reduced-dose
eparin is unknown.
The prespecified primary safety and efficacy end points
ere based on the intention-to-treat principle among pa-
ients who received any dose of study drug. For the pre-
pecified continuous ECG analysis, patients were required
o have at least 48 h of interpretable data. Analyses were
erformed using 2-sided tests at the 0.05 level of signifi-
ance. No adjustments were made for multiple comparisons.
Baseline characteristics and safety and efficacy end points
ere summarized using descriptive statistics, including
ean values  SD, median values with interquartile ranges,
nd event rates, as appropriate, using SAS version 9.1 (SAS
nstitute, Cary, North Carolina). Differences between
NAPc2 and placebo were analyzed via Fisher exact test
binary outcomes), t tests (continuous normally distributed
ata), and the Wilcoxon rank sum test (continuous non-
ormally distributed data). Comparisons involving more
han one rNAPc2 dose were performed using the chi-square
est (binary outcomes), 1-way analysis of variance (contin-
ous normally distributed data), and Kruskal-Wallis test
continuous non-normally distributed data). The Pearson
orrelation test was used to assess the correlation of log
oncentration rNAPc2 with INR.
The trial was designed as a collaborative effort between
he TIMI Study Group, the Nottingham Clinical Research
imited (NCRL), and the sponsor. The data were collected
y NCRL. The NCRL and the TIMI Study Group
erformed the prespecified and exploratory analyses inde-
endently of the sponsor.
esults
atients. Baseline characteristics are shown in Table 1 and
oncomitant treatments in Table 2 (see Appendix for
omplete data in each dose panel). No significant differences
ere found between patients who received rNAPc2 or
lacebo.
harmacokinetics and pharmacodynamics. Dose-related
ncreases in plasma rNAPc2 concentration and INR were
bserved at 2 to 6 and 48 h (Fig. 3). The log concentration
as correlated with INR at 2 to 6 and 48 h (  0.51 and
 0.49, respectively; p  0.0001 for both). Patients who
eceived increasing doses of rNAPc2 had progressively less
hrombin generation (lower F1.2) at 2 to 6 h (trend p 
.001) and 48 h (trend p  0.002), with statistically
ignificant reductions observed with doses 7.5 g/kg
ompared with placebo (Fig. 4).
ontinuous ECG. The rate of ischemia by continuous
CG through day 7 was similar in patients receivingNAPc2 and placebo (18% vs. 21%; p  NS). At doses of
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June 26, 2007:2398–407 The ANTHEM–TIMI-32 Trial: TF/FVIIa Inhibitor in nSTE-ACSNAPc2 that suppressed F1.2 through 48 h (7.5 g/kg),
schemia was reduced by 50% using a variety of continu-
us ECG measures compared with low-dose rNAPc2 and
lacebo (Table 3).
iomarkers. There were no differences (absolute concen-
rations or change from baseline) in cardiac troponin I,
igh-sensitivity C-reactive protein, brain natriuretic pep-
ide, or matrix metalloproteinase-9 through 42 days across
reatment groups in the dose-ranging phase or when com-
aring all patients who received rNAPc2 versus placebo
data not shown).
afety. There were 9 significant hemorrhages (3.5%), in-
luding 4 major and 5 minor, in the entire trial; all were
ssociated with a procedure. In dose ranging, there was no
ifference in the incidence of significant hemorrhage be-
ween rNAPc2 and placebo (4.3% for the pooled doses of
.5 to 10 g/kg rNAPc2 vs. 2.5% for placebo; p  NS). No
tatistical trend was observed across ascending doses of
NAPc2 individually (Fig. 5) or when grouped as placebo,
ow-dose (1.5 to 5.0 g/kg), and high-dose (7.5 g/kg;
.5% vs. 2.9% vs. 4.5%, respectively; p  0.77). All 4 major
emorrhages occurred at the highest dose (10 g/kg); 3
ere patients with excessive bleeding requiring transfusions
fter CABG. A shorter interval between the last dose of
NAPc2 and CABG surgery was associated with a higher
isk of bleeding (40% vs. 10% vs. 0% for surgery performed
48 h vs. 48 to 96 h vs. 96 h, respectively, after the last
ose of study drug; trend p  0.077). Other safety out-
omes, including rates of other (neither major nor minor)
leeding (9.8% vs. 10.0%), frequency (6.5% vs. 2.5%) and
verage number (2.2 vs. 2.0) of units of red blood cell
atient Baseline Characteristics
Table 1 Patient Baseline Characteristics
Placebo rNAPc2
Number of patients 40 215
Median age, yrs 56 58
Women, % 20 34
History of myocardial infarction, % 35 33
Prior percutaneous coronary intervention, % 55 41
Prior coronary artery bypass graft surgery, % 15 20
History of congestive heart failure, % 8 9
History of hypertension, % 80 78
History of diabetes mellitus, % 33 34
History of dyslipidemia, % 88 79
Presenting non–ST-segment elevation myocardial
infarction, %
50 53
ST-segment deviation 0.5 mm at presentation, % 45 47
Mean TIMI risk score (SD) 4.0 (1.2) 3.7 (1.3)
Low risk (1 to 2), % 5 16
Intermediate risk (3 to 4), % 68 57
High risk (5 to 7), % 28 27
Mean systolic blood pressure (mm Hg) 127 130
Median creatinine clearance (ml/min) 111 102
here were no significant differences between treatment groups.
rNAPc2  recombinant nematode anticoagulant protein c2; TIMI  Thrombolysis In Myocardial
nfarction.ransfusions, and serious adverse events (33% vs. 30%) were cimilar between rNAPc2 and placebo, respectively (all p 
S). No patients required treatment with fVIIa concentrate
o reverse rNAPc2 anticoagulation (18). Three patients
eceiving rNAPc2 developed mild thrombocytopenia
93,000, 98,000, and 99,000 cells/mm3) with no clinical
equelae.
Anti-rNAPc2 antibody formation occurred in 13% of
atients receiving rNAPc2. No patients with positive anti-
odies experienced symptoms (e.g., allergic reaction, ana-
hylaxis) attritibutable to the antibody, nor were there
ifferences in INR or clinical outcomes among those with or
ithout antibodies.
linical events. Clinical event rates were low and there
ere no differences in the rates of death, reinfarction,
linical recurrent ischemia, stroke, and late revascularization
ither individually or in composite between the treatment
roups (Table 4). The composite event rate was 24% among
atients receiving higher dose (7.5 g/kg) rNAPc2 versus
8% for placebo (p  0.15). Thrombotic bailout with an
pen-label antiocoagulant occurred in 5 patients during
eparin de-escalation, all whom received rNAPc2 10 g/kg
nd no heparin (19% vs. 0% for no-heparin vs. half-dose
eparin treatment groups, respectively; p  0.051). Of the
4 patients who had PCI in the no-heparin group, 4 had
BO (new intrastent or coronary artery thrombus forma-
ion). The fifth TBO event was an episode of clinical
nstable angina without new ischemic ECG changes that
equired an increased dose of intravenous nitroglycerin and
pen-label anticoagulation before PCI.
n-Hospital Therapies and Procedures
Table 2 In-Hospital Therapies and Procedures
Placebo rNAPc2
Doses of study drug, %
1 83 85
2 18 14
3 0 1
Enoxaparin,* % 75 71
Unfractionated heparin,* % 33 33
Aspirin 100 100
Initial dose 300 mg, % 85 82
Maintenance dose 300 mg, % 82 78
Clopidogrel 85 81
Loading dose 300 mg, % 38 35
Loading dose 300 to 599 mg, % 59 53
Loading dose 600 mg, % 3 11
Intravenous glycoprotein IIb/IIIa blocker,† % 53 53
Predischarge PCI, % 60 47
Hours after randomization, median
[25%, 75%]
5.7 [1.9, 21] 4.6 [1.8, 19]
Predischarge CABG surgery, % 3 11
Hours after randomization, median
[25%, 75%]
139 [NA] 88 [60, 115]
here were no significant differences between treatment groups. *Patients in dose ranging only
ncluded. †92% eptifibatide, 4.4% tirofiban, 3.7% abciximab.
CABG  coronary artery bypass graft; NA  not applicable (only 1 patient); PCI  percutaneous
oronary intervention; rNAPc2  recombinant nematode anticoagulant protein c2.
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his is the first randomized trial of a proximal inhibitor of
he coagulation cascade that targets TF in patients with
CS. We found that intravenous rNAPc2 in doses of 1.5 to
0 g/kg was well tolerated in patients with nSTE-ACS
anaged with multiple antithrombotic agents and an early
nvasive strategy. However, all 4 observed major hemor-
hages occurred with the highest dose. The INR was
ncreased and new thrombin generation (measured by F1.2)
as suppressed in a dose-dependent fashion that correlated
ith plasma drug concentration. We observed 3 important
ssues with regard to the bleeding risk of rNAPc2. First,
imilar to other antithrombotic agents, the risk of bleeding
s highest around the time of procedures. Indeed, all
ignificant hemorrhages were related to the femoral access
Figure 3 Pharmacokinetics and Pharmacodynamics
(A) Increasing doses of recombinant nematode anticoagulant protein c2 (rNAPc2)
concentrations at 2 to 6 and 48 h. (B) rNAPc2 increased the international normalite or CABG surgery. Second, there was no statistical ancrease in bleeding rates with rNAPc2 (all doses pooled)
ompared with placebo, a result that is consistent with
n vitro modeling of rNAPc2 and various antithrombotic
gents that demonstrated no exaggerated effect on clotting
nd platelet function (13). However, in the subgroup of
atients undergoing CABG, we observed a tendency toward
ncreased bleeding rates with surgery performed 48 hours
f rNAPc2 administration, particularly following the high-
st dose studied (10 g/kg).
Suppression of ischemia on continuous ECG has been
ssociated with a reduction in clinical ischemic events in
tudies with enoxaparin (19) and GP IIb/IIIa blockers (20),
ncluding patients who underwent PCI (21). A novel
nding in the ANTHEM–TIMI-32 trial was that the doses
f rNAPc2 that suppressed F1.2 through 48 h were also
ssociated with increased plasma drug
tio (INR) in a dose-related fashion at 2 to 6 and 48 h.were a
ized rassociated with a 50% reduction in ischemia on continu-
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ction of this drug and the hypothesized benefit in patients
ith plaque rupture and vessel wall injury. A larger trial
ould be required to test the hypothesis that rNAPc2
educes clinical events, because the current trial was not
owered for such an assessment. Because rNAPc2 has a
alf-life of 50 to 60 h and can be administered subcutane-
usly, prolonged inhibition of new thrombin generation
ith rNAPc2 for several weeks has the potential to improve
he recommended discharge regimen after ACS, which
urrently does not include routine use of an anticoagulant.
Although several small studies have explored the use of
educed-dose UFH (22) or no heparin (23) during PCI, the
isk of intraprocedural thrombosis remains a concern (24).
n the ANTHEM–TIMI-32 trial, we observed thrombotic
omplications in 5 of 26 patients (19%) who were treated
ith 10 g/kg rNAPc2 without UFH. However, no throm-
otic complications occurred when half-dose UFH was
dministered. In 4 out of 5 cases of TBO, new intracoronary
hrombus formed during PCI. Catheter-related thrombosis
as been reported more frequently with the parenteral factor
Figure 4 rNAPc2 Suppresses New Thrombin Generation
Prothrombin fragment 1.2 (F1.2), a marker of new thrombin generation, was reduc
nematode anticoagulant protein c2 (rNAPc2) compared with placebo. Lower-dose r
Continuous 3-Lead Electrocardiographic Results
Table 3 Continuous 3-Lead Electrocardiogra
Plac
Evaluable data, n 34
Median duration of recording, days 6
Any ischemia present, % 21
Mean number of episodes per patient 0
Average duration of ischemia per patient (min) 23
Average ST-product* per patient (mm·min) 29*ST-product  maximal extent of ST-segment depression (in millimeters) 
rNAPc2  recombinant nematode anticoagulant protein c2.a inhibitor fondaparinux than UFH despite flushing cath-
ters with heparin (25). Similarly, thrombus formation on
he guiding catheter and wire has been reported with
noxaparin despite concomitant therapy with aspirin, clopi-
ogrel, and GP IIb/IIIa blockers (26).
These observations, although small in number, raise the
ossibility that inhibitors of the terminal portion of the
oagulation cascade (i.e., “distal protection”) may be neces-
ary during intravascular procedures to inhibit thrombin.
istally acting agents may be more effective in inhibiting
he contact pathway that is activated when catheters are
ntroduced into the bloodstream (27). Although proximal
nhibitors of the clotting cascade may be more effective in
educing thrombin generation, even with high doses of a
roximal inhibitor, thrombus formation can still occur when
oreign bodies are present and heparin is withheld. The
resent data are consistent with emerging clinical (25,26)
nd experimental (27) data which suggest that concomitant
nhibitors of the contact pathway that act on formed
hrombus may be necessary during intracoronary proce-
ures. Therefore, we believe that reduced-dose distal-acting
nficantly at 2 to 6 and 48 h with 7.5 g/kg recombinant
(1 to 5 g/kg) blunted the increase in F1.2 seen at 48 h in the placebo group.
Results
rNAPc2 (Dose in g/kg)
3-Way p Value1.5 to 5.0 7.5 or 10
93 97 —
6.7 6.0 NS
27% 9.3% 0.007
1.01 0.30 0.06
32 4.8 0.02
53 9.1 0.03ed sig
NAPc2phic
ebo
.9
%
.59duration of ischemia (in min).
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The ANTHEM–TIMI-32 Trial: TF/FVIIa Inhibitor in nSTE-ACS June 26, 2007:2398–407ntithrombins should be tested in combination with prox-
mal inhibitors currently in development.
tudy limitations. This phase 2 trial was not designed with
ufficient power to exclude small differences in safety or
linical efficacy. The trial enrolled moderate- to high-risk
atients in whom an early invasive strategy was planned and
ABG was not intended; therefore, the observed results
ay not apply to other patients. We did not control for
rior therapies and concurrent treatments (other than anti-
hrombotics), which may have affected the biomarkers and
utcomes. Too few patients (on average 3 per panel)
eceived more than 1 dose of rNAPc2 to draw any mean-
ngful conclusions from the administration of multiple
oses. The heparin de-escalation phase was open label
ithout concurrent controls.
Figure 5 Hemorrhagic Events With rNAPc2
There was no difference between the rates of major plus minor hemorrhage amon
placebo (3.7% vs. 2.5%, respectively), nor was there a trend across ascending dos
were spontaneous. *3/4 major hemorrhages were CABG-related, 2 to 3 days after
hemorrhage; TIMI  Thrombolysis In Myocardial Infarction; UFH  unfractionated h
linical Events Through 42 Days
Table 4 Clinical Events Through 42 Days
Placebo (n  40) rNAPc2 (n  215)
All-cause mortality 0% 0%
New myocardial infarction* 3% 3%
Clinical recurrent ischemia* 8% 8%
Any of the above 3 10% 11%
Ischemia on continuous ECG* 21% 18%
Revascularization after discharge 13% 10%
Stroke 0% 0.5%
Any of the above 38% 31%
here were no significant differences between treatment groups. *Blinded, centrally adjudicated
vents.
ECG  electrocardiogram; rNAPc2  recombinant nematode anticoagulant protein c2.onclusions
n patients with nSTE-ACS managed with standard ther-
pies including an early invasive approach, addition of
NAPc2, a potent inhibitor of the TF/fVIIa complex, at
oses up to 10 g/kg, was well tolerated. The observation
hat doses 7.5 g/kg suppressed F1.2 (a marker of
hrombin generation) may explain the observed 50%
eduction in ischemia detected by continuous ECG. Some
eparin may be necessary to prevent catheter-based throm-
osis. Coronary artery bypass graft surgery should be
voided within 48 hours of dosing. Future trials of rNAPc2
n nSTE-ACS are needed to assess the potential clinical
ole of this novel agent.
eprint requests and correspondence: Dr. Robert P. Giugliano,
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oston, Massachusetts 02115. E-mail: rgiugliano@partners.org.
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